Additionally, a health care provider will guide you through switching so it’s done safely. Experts highly emphasize the need for close medical supervision for both Zepbound and Ozempic.

To learn more about the dosages for all uses of these drugs, see the Zepbound dosage article and Wegovy dosage article. If you have questions about dosing when switching from Wegovy to Zepbound or ...

it’s worth asking your doctor whether Zepbound might be a better fit,” he advised. However, if you’re doing well on Wegovy, there’s no need to switch, he noted. Of course, it’s important ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass. “For that to ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S ...

and Zepbound (tirzepatide) are no longer in shortage. That means consumers who've used compounded weight-loss drugs via telehealth providers will soon need to switch to brand name drugs or pursue ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in adults as part of a shift in addressing the global obesity epidemic, as reported by Reuters. In a memo ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.